The yearly MetaSystems Distributor Meeting (DM), brought into life in 2002 as a platform to gather all international partners of MetaSystems and other members of the global MetaSystems family, just ended last week. The DM is being organized in turns by MetaSystems Headquarters, MetaSystems USA (MGI), and MetaSystems Asia. Since MGI is celebrating its 25th anniversary in 2018 they decided to choose a special location: Nassau, The Bahamas!
Translocation/Dual Fusion Probe
- Order Number
- Package Size
- 100 µl
Several recurrent balanced translocations and inversions, and their variants, are recognized in the WHO category acute myeloid leukemia (AML) with recurrent genetic abnormalities. Furthermore, several cytogenetic abnormalities are considered sufficient to establish the WHO diagnosis of AML with myelodysplasia-related features when 20% or more blood or marrow blasts are present.
AML M3 and AML M3v are characterized by a reciprocal translocation between the long arm of chromosome 15 and the long arm of chromosome 17. This translocation leads to a rearrangement of the PML-gene situated on chromosomal band 15q24 and the RARA-gene situated on band 17q21. The PML-RARA-rearrangement has gained major clinical importance as combining ´all transretinoic acid´ and conventional anthracy-cline-cytarabin based chemotherapy has improved the prognosis in this subgroup of AML dramatically.
- Acute Myelogenous Leukemia (AML)
Two green (2G) and two orange (2O) signals.
Aberrant Cell (typical results):
One green (1G), one orange (1O), and two green-orange signals (2GO).
- Lafage-Pochitaloff et al (1995) Blood 85:1169-1174
- Grimwade et al (2000) Blood 96:1297-1308
- Schoch et al (2002) Hematol-J 3:259-263